Clinical safety of the selective PKC-&bgr; inhibitor, ruboxistaurin

Author： McGill Janet B   King George L   Berg Paul H   Price Karen L   Kles Keri A   Bastyr Edward J   Hyslop David L  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.5, Iss.6, 2006-11, pp. : 835-845

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ruboxistaurin: PKC-β inhibition for complications of diabetes

By Danis Ronald P   Sheetz Matthew J  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 17, 2009-12 ,pp. : 2913-2925

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor

By Antoniou Katerina   Malamas Michael   Drosos Alexandros A  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1719-1732

Informa Healthcare

Access to resources Recommend Favorite

The protein kinase C-β inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications

By Vinik Aaron  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 12, 2005-12 ,pp. : 1547-1559

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Reboxetine, a Selective Norepinephrine Reuptake Inhibitor for the Treatment of Patients with Depression

By Fleishaker J.C.  

Clinical Pharmacokinetics, Vol. 39, Iss. 6, 2000-12 ,pp. : 413-427

Adis International

Access to resources Recommend Favorite

Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitor

By Patrignani Paola   Capone Marta L   Tacconelli Stefania  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 2, 2003-02 ,pp. : 265-284

Informa Healthcare

Access to resources Recommend Favorite